Clinical trials: Cancer, Digestive System
Colorectal Cancer
Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study
Colorectal carcinoma (CRC) is the third most common malignancy worldwide. In Egypt, the relative frequency of CRC is about 9-12% with high male predominance 3:1.
- Trial name
- NCT05601388
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent
Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia
This study aimed to evaluate the effects of the ACTIVE-Care Integrated Physical Activity-Based Supportive Care Program on cancer-related fatigue, hope, and psychological resilience in adolescents with acute lymphoblastic leukemia…
- Conditions
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent, Resilience, Psychological, Physical Activities
- Trial name
- NCT07882069
- Testing
- ACTIVE-Care Integrated Physical Activity-Based Supportive Care Program
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Selcuk University
Carcinoma, Peritoneal Neoplasm
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
Two days prior to planned surgery, paclitaxel is infused IV over 24 hours. Patients will undergo cytoreductive surgery, to debulk tumor.
- Trial name
- NCT00001569
- Testing
- Cisplatin, Paclitaxel, 5-FU
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Esophagectomy, No Signs of Cancer Recurrence
Pylorus Dysfunction After Esophagectomy and Gastric Tube Reconstruction. Effect of Pneumatic Pylorus Dilatation During Hospital Stay, Surgical Complications During in Hospital Stay
Delayed emptying of the gastric tube after esophagectomy is a frequent and durable problem. No treatment is currently available.
- Conditions
- Esophagectomy, No Signs of Cancer Recurrence, Delayed Gastric Emptying
- Trial name
- NCT02086461
- Testing
- Pneumatic pyloric dilatation, 15 mm pyloric balloon dilatation
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Pancreas Cancer, Diabetes
Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery
The primary aim of the present study is to examine the effect of a "structured follow-up intervention" to be performed in the first three months after PD on blood glucose.
- Trial name
- FiGluR (NCT06774170)
- Testing
- structured follow-up intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Dokuz Eylul University
Gastric Cancer
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
To facilitate the early gastric cancer diagnosis, an assay based on assessing large-scale methylation and fragmentation profiles of the plasma cell free (cfDNA) will be developed and validated.
- Trial name
- NCT05668910
- Testing
- whole genomic methylation and fragmentation profile analysis of cfDNA
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GeneCast Biotechnology Co., Ltd.
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Hepatocellular Carcinoma
Role of DEB-TACE Versus c-TACE in Treatment of HCC
Hepatocellular carcinoma (HCC) is listed as the sixth most common cancer worldwide and the third most frequent cause of cancer-related mortality. The majority of HCC cases occurs stem from chronic liver disease and cirrhosis.
- Trial name
- NCT05093920
- Testing
- Doxorubicin-Eluting Beads
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Liver Cancer
Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear.
- Trial name
- NCT01434524
- Testing
- LIVACT
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Kochi University
Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
This randomized study examines how well zinc works in improving quality of life in patients with gastrointestinal cancer that cannot be removed by surgery who are receiving chemotherapy.
- Conditions
- Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Unresectable Esophageal Carcinoma, Unresectable Pancreatic Carcinoma
- Trial name
- NCT03819088
- Testing
- Zinc
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Colon Cancer
International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer
The T-REX study aims to clarify the actual status of metastatic lymph node (LN) distribution in colon cancer and provide reliable evidence regarding the optimal length of bowel resection and the extent of central lymph node…
- Trial name
- T-REX (NCT02938481)
- Where
- 36 sites in Germany, Japan and 5 more
- Volunteers
- 3,647 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Advanced Solid Tumors
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates.
- Trial name
- NCT01178411
- Testing
- Tivantinib, Anti-Cancer Combination Therapy
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Adenoma, Adenoma Colon
Impact of AI on Trainee ADR
Adenoma detection rate (ADR) is a validated quality metric for colonoscopy with higher ADR correlated with improved colorectal cancer outcomes.
- Conditions
- Adenoma, Adenoma Colon, Colorectal Cancer
- Trial name
- NCT05423964
- Testing
- AI use in Endoscopy Room, Non-AI use Standard of Care endoscopy room
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Glioblastoma, Squamous Cell Carcinoma
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO.
- Conditions
- Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT05974410
- Testing
- AVM0703, Hydrocortisone, Proton pump inhibitor
- Sponsor
- AVM Biotechnology Inc
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Colorectal Cancer (CRC), Pancreatic Cancer
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency.
- Conditions
- Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06751524
- Testing
- Botensilimab, Balstililmab
- Sponsor
- Agenus Inc.
Peritoneal Carcinomatosis, Pseudomyxoma Peritonei
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.
- Conditions
- Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Peritoneal Mesothelioma
- Trial name
- HIPEC (NCT01617382)
- Where
- Belgium
- Volunteers
- 125 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer
Colonoscopic Skill Acquisition and Transfer Via Simulated Curriculum of Progressive Training
It is hypothesized that a progressive simulated learning strategy will result in better global clinical performance (e.g., technical, communication) and transfer of endoscopic skill, as compared with a high-fidelity simulation…
- Trial name
- NCT02000180
- Testing
- Progressive Group
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon-gamma may interfere with the growth of tumor cells and slow the growth of the tumor.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00002796
- Testing
- fluorouracil, sodium phenylbutyrate, indomethacin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.